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The study population of this trial, 532 soldiers of Battalion 408 of the Indonesian Army standing formation (foreground) after
disembarking from their troop transport ship (background) at Tanjung Mas harbor, Semarang, Central Java, on 28 February 2013.
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Abstract
Background: Safety and efficacy of primaquine against repeated attacks of Plasmodium vivax depends upon
co-administered blood schizontocidal therapy in radical cure. We assessed primaquine (PQ) as hypnozoitocide
when administered with dihydroartemisinin-piperaquine (Eurartesim®, DHA-PP) or artesunate-pyronaridine
(Pyramax®, AS-PYR) to affirm its good tolerability and efficacy. A third arm, artesunate followed by primaquine,
was not intended as therapy for practice, but addressed a hypothesis concerning primaquine efficacy without
co-administration of blood schizontocide.
Methods: During March to July 2013, an open-label, randomized trial enrolled Indonesian soldiers with vivax
malaria at Sragen, Central Java, after six months duty in malarious Papua, Indonesia. No malaria transmission
occurred at the study site and P. vivax recurrences in the 12 months following therapy were classified as relapses.
A historic relapse control derived from a cohort of soldiers who served in the same area of Papua was applied to
estimate risk of relapse among randomized treatment groups. Those were: 1) AS followed 2d later by PQ (0.5 mg/kg daily
for 14d); 2) co-formulated AS-PYR concurrent with the same regimen of PQ; or 3) co-formulated DHA-PP concurrent with
the same regimen of PQ.
Results: Among 532 soldiers, 219 had vivax malaria during the four months following repatriation to Java; 180 of
these were otherwise healthy and G6PD-normal and enrolled in the trial. Subjects in all treatment groups tolerated the
therapies well without untoward events and cleared parasitemia within three days. First relapse appeared at day 39
post-enrollment, and the last at day 270. Therapeutic efficacy of PQ against relapse by incidence density analysis was
92 % (95 %CI = 83–97 %), 94 %(95 %CI = 86–97 %), and 95 %(95 %CI = 88–98 %) when combined with AS, AS-PYR, or
DHA-PP, respectively.
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Conclusions: This trial offers evidence of good tolerability and efficacy of PQ against P. vivax relapse when administered
concurrently with DHA-PP or AS-PYR. These offer alternative partner drugs for radical cure with primaquine. The AS arm
demonstrated efficacy with a total dose of 7 mg/kg PQ without concurrently administered blood schizontocide, another
option when primaquine therapy is removed in time from the treatment of the acute malaria or applied presumptively
without an attack.
Trial registration: Current Controlled Trials ISRCTN82366390, assigned 20 March 2013.
Keywords: Malaria, Plasmodium vivax, Relapse, Primaquine, Efficacy
Background
Plasmodium vivax threatens nearly three billion people
and sickens tens of millions annually [1]. Improper or
delayed treatment may lead to severe and fatal outcomes
associated with severe anemia, severe thrombocytopenia,
respiratory distress, renal failure, hepatic dysfunction,
coma, or shock [2, 3]. Unlike, Plasmodium falciparum,
P. vivax places latent stages called hypnozoites in the
liver after inoculation of mosquito-borne sporozoites.
Hypnozoites later awaken and provoke renewed clinical
attacks, each causing debilitating illness with risk of
threatening complications and onward transmission.
In tropical Southeast Asia, P. vivax relapse behaviors
resemble those in the Chesson strain from New Guinea
[4, 5]. “Chesson-like” strains relapse quickly, repeatedly,
and at approximately two-month intervals in almost all
patients. In Thailand and Indonesia, relapse occurred
among nearly 80 % of patients within two months [6, 7].
Among others treated for acute falciparum malaria,
51 % suffered P. vivax attacks within two months [6].
Relapse likely accounts for most attacks of vivax malaria
where Chesson-like P. vivax occurs [8, 9]. Therapeutic
success against hypnozoites may thus be appreciated as
an important clinical and public health objective.
Radical cure of vivax malaria includes blood schizonto-
cidal and hypnozoitocidal therapies. In 1952 the United
States licensed the 8-aminoquinoline primaquine com-
bined with the 4-aminoquinoline chloroquine for radical
cure of P. vivax malaria. Primaquine remains the only op-
tion against relapse, although another 8-aminoquinoline,
the investigational drug tafenoquine, approaches licensure
[10]. Newer blood schizontocidal therapies must be com-
bined with primaquine in radical cure because resistance
to chloroquine by P. vivax often occurs, especially in
Southeast Asia [11]. Resistant strains of P. vivax dominate
across the Indonesian archipelago, and chloroquine was
abandoned in favor of artemisinin-combined therapies
(ACT) therapies over a decade ago [12].
Authoritative recommendations for the use of ACTs for
treatment of acute P. vivax malaria cite good evidence of
efficacy [13, 14]. However, no evidence yet attests to
primaquine safety and efficacy when co-administered with
most of those therapeutic options. The importance of
such evidence has been highlighted by historic examples
of drug-drug interactions (DDI) profoundly impacting
both the safety and efficacy of 8-aminoquinolines [15].
Frontline therapy for acute P. vivax in Indonesia is the
ACT dihydroartemisinin-piperaquine (DHA-PP) [12]. We
reported good safety and efficacy of primaquine against
relapse when administered 25 days after DHA-PP therapy,
a delay imposed by the unexamined possibility of DDI [7].
Later studies affirmed no DDI issues with co-administered
DHA-PP and primaquine [16]. The current study aimed
to evaluate the safety and efficacy of primaquine ad-
ministered concurrently with DHA-PP. We also evalu-
ated primaquine co-administered with another ACT,
artesunate-pyronaridine (AS-PYR) given recent evi-
dence indicating a lack of significant pharmacokinetic
interaction with primaquine [17]. Both of these blood
schizontocidal therapies have very good efficacy against
asexual blood stages of P. vivax [18–21].
The trial included a third treatment arm, artesunate
[22] followed by primaquine. That arm was not intended
as therapy for practice, but was an independent experi-
mental arm testing the hypothesis that primaquine may
require concurrent administration of partner blood schi-
zontocides for good efficacy [15]. A trial in the 1950s
demonstrated primaquine failure against relapse when
administered after quinine rather than concurrently [23].
We recruited Indonesian soldiers exposed to malaria
in eastern Indonesia after returning to a site in Central
Java free of malaria transmission [24]. In addition to the
distinct advantage of classifying recurrent malaria as
relapses with a high degree of certainty, the infections
were by the chloroquine-resistant and primaquine-
tolerant Chesson-like P. vivax strains dominating
eastern Indonesia [25].
Methods
Study design, setting and patient population
A single center, randomized, open-label primaquine ef-
ficacy trial enrolled Indonesian soldiers with P. vivax
malaria after returning from malarious Papua (Fig. 1)
[24]. The study took place at an army base at Sragen,
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Central Java, between March 2013 and July 2014. The trial
team established permanent residence, offices, clinic, phar-
macy, and laboratory on that base.
The battalion identified for study returned to Java by
ship, disembarking at Tanjung Mas at Semarang on 28
February 2013. Routine microscopic screening for malaria
at portside revealed 67 of 536 soldiers had malaria (30 P.
falciparum, 33 P. vivax, and 4 mixed infections). These
soldiers received treatment according to national guide-
lines [12], but not primaquine because screening for
glucose-6-phosphate dehydrogenase (G6PD) deficiency
was not available. The soldiers departed on liberty to visit
with families prior to returning to base. They had done so
by 20 March 2013, when study familiarization began, in-
cluding emphasis on the importance of voluntary consent.
Enrollments commenced on 29 March 2013.
Soldiers on base faced no known risk of acquiring
malaria locally. Sragen District (population 896,201
residents) occupies 942 km2 with an average density of
947 residents/km2 with 25 primary health care centers
and 10 hospitals. During 2012–2013, authorities re-
ported eight malaria cases, all imported. No known
cases of locally acquired malaria were reported during
2013–2014. Reinfection at Sragen was highly improbable.
Eligibility and randomization
Consenting soldiers with confirmed P. vivax were
screened for eligibility by obtaining a medical history,
and conducting physical and laboratory examinations
that included electro-cardiogram (ECG; BTL-08, BTL
Industries, Framingham, MA, USA; 12-lead, 50 mm/s,
10 mm/mV), complete blood counts (Coulter Ac-T;
Beckman Coulter, Fullerton, CA, USA), full blood chem-
istry panel (Cobas-111, Roche, Rotkreuz, Switzerland),
and G6PD deficiency screening (NADPH kit 203A,
Trinity Biotech, Wicklow, Ireland). Eligible subjects had
uncomplicated vivax malaria, were not under treatment
for another illness, had not recently consumed antima-
larials, and showed normal ECG, blood laboratory
values, and G6PD activity by fluorescent spot testing
(Trinity Biologics, Ireland).
The trial statistician block-allocated treatment assign-
ments by varying blocking number at random [26]. A
plain, consecutively numbered and sealed envelope pre-
pared by the trial administrator contained therapy assign-
ment and was opened in sequence as each eligible and
consenting soldier enrolled. The study pharmacist super-
vised therapy and adherence to assigned treatment, includ-
ing direct observation of each of the daily 14 doses of PQ.
Study treatments
Groups received one of the following treatments under
directly observed, signature-affirmed supervision by a
member of the research team:
AS + PQ – 200 mg AS (Arsuamoon®; a 50-mg artesu-
nate tablet co-packaged with an amodiaquine hydro-
chloride tablet [discarded]; Guilin Pharmaceuticals Co.
Ltd., Shanghai, China) was administered, followed by a
daily dose of 100 mg daily for six days. After a 48-hour
pause for AS washout, PQ was administered with a daily
dose of two tablets, each containing 15 mg PQ base for
14 days. As in all other groups, Sanofi Pharmaceuticals
(PRIMAQUINE®, Primaquine phosphate tablets USP
26.3 mg, 15 mg equivalent base, Sanofi-Aventis Canada
Inc. Laval, Quebec) provided the PQ administered.
AS-PYR + PQ – single daily dose of three tablets, each
containing 60 mg AS and 180 mg of PYR provided as
Pyramax® from Shin Poong Pharmaceuticals, Seoul,
South Korea, for three days given concurrently with a
daily dose of 30 mg PQ base for 14 days.
DHA-PP + PQ – a single daily dose of three tablets,
each containing 40 mg DHA and 320 mg of PP base
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Fig. 1 Plasmodium vivax in Indonesia and location of exposure of study battalion. Map of Indonesia illustrating predicted prevalence of P. vivax in
2010 published elsewhere [24]. Black box at far right indicates the area where both a prior study battalion [7] and the current one were exposed
to risk of infection, and the black box at center left indicates location of the current study site in Central Java
provided as Eurartesim® from Sigma-Tau Industrie Farm-
aceutiche Riunite S.p.A., Pomezia, Rome, Italy, for three
days given concurrently with a daily dose of 30 mg PQ
base for 14 days.
Subjects weighing >70 kg were treated as above except
instead receiving 45-mg daily dose PQ (three tablets) for
14 days, five daily AS tablets instead of four, and four ra-
ther than three tablets of either AS, AS-PYR or DHA-PP
daily. All subjects were offered a non-fatty carbohydrate
snack prior to dosing to mitigate stomach upset caused
by PQ [27]. Subjects were monitored for an hour and
dosing repeated if vomiting occurred.
Follow-up
Physical complaints and methemoglobin (Masimo Blood
Oximeter, Masimo Corp., Irvine, CA, USA) were re-
corded daily during therapy. Routine blood film exami-
nations occurred on days 3, 7, 14, 21, 28, 35, 42, 56, 63,
70, 84, 126, 140, 180, and 365 post-enrollment. Subjects
reporting to the clinic with illness were examined the
same day. Subjects positive for P. vivax received DHA-PP
+ PQ (0.5 mg/kg/day × 14 days) and were released from
study after 28 days. Subjects not relapsing were followed
for one year.
Endpoints and definitions
Primary endpoint was incidence density (events/person-
year) of first relapse by P. vivax in the year following
radical cure. Patients reaching that endpoint contributed
time at risk up to that event or withdrawal. Microscopic
diagnoses of P. vivax were confirmed by another micro-
scopist on site, and later by a blinded third microscopic
read in Jakarta. Blood blots were collected onto Whatman
FTA Classic™ filter paper for PCR confirmation of the
diagnosis, and DNA extracted (QIAmp DNA Blood
Mini™) before nested PCR Plasmodium genus-specific
primers (Nest 1) and then with species-specific primers
for Nest 2 as detailed elsewhere [28]. Secondary endpoints
included frequencies of physical complaints, laboratory
abnormalities, reported adverse events of grade 3 or
higher during treatment, and serious adverse events
possibly, probably, or definitely related to study treat-
ment at any time during treatment or follow-up.
Statistical considerations
We powered the trial for precision in independent esti-
mates of PQ efficacy when combined with AS, AS-PYR,
or DHA-PP. The precision estimate was derived itera-
tively through analysis of binomial distribution of vari-
ance around a predicted 98 % efficacy [7]. A sample size
of 60 individuals per arm delivered the desired 3.5 %
precision around the estimate of efficacy.
The primary endpoint of incidence density informed
the estimate of efficacy derived from a relapse control.
That control adjusts for geographic variability in relapse
attack rates [4, 29]. We employed a relapse control co-
hort from a previous study [7] as relapse control in the
current study. The cohort came from a prior battalion of
study from Lumajang, East Java. They had been de-
ployed to precisely the same locale in Papua as the
current battalion of study at Sragen, Central Java. We
reasoned the relapse attack rate would be similar. Thera-
peutic efficacy among treatment groups at Sragen was
thus calculated using incidence density of relapse control
(IDAS-Lumajang) against incidence density (ID) of recur-





The 95 % confidence interval (CI) for each of the three
estimates of efficacy was calculated from the binomial
distribution.
Incidence density of relapse represents the preferred
mathematical treatment for events occurring over pro-
longed periods [30, 31]. Like efficacy of chemoprophylaxis
against malaria [32], incidence density within groups was
the number of P. vivax attacks divided by the sum of
person-years at risk at end of study. Therapeutic efficacy
expressed as proportion of subjects remaining free of
recurrence after six months was included in this trial
analysis for sake of reference to other hypnozoitocidal
trials where reinfection possibly confounded recurrence
rates [10].
Ethics
Institutional ethics review boards of the Faculty of Medi-
cine, University of Indonesia (ref.no. 13/H2.F1/ethic/2013)
and the Centre for Tropical Medicine, Nuffield Department
of Medicine, University of Oxford (ref.no.179-12) reviewed
and approved a protocol detailing this trial. Indonesian food
and drug regulatory authorities (Badan Pengawasan Obat
dan Makanan, Jakarta; ref.no. PN.01.06.313.03.13.998) ap-
proved and monitored this trial.
Results
Patients and procedures
Figure 2 illustrates screening and enrollment during
March-July 2013. Table 1 lists baseline demographic, la-
boratory and clinical characteristics among the ran-
domized treatment groups. Subjects were 21–50 years
old (mean 29–30 yr; P = 0.54), weighed 52–88 kg
(means 67–71 kg; P = 0.045), and had parasitemias of P.
vivax (confirmed by PCR) ranging from 16–9,488/μL
(median 744-888/μL; P = 0.94). Fever (>37.5 °C) oc-
curred in 22–30 % among groups (P = 0.72). No signifi-
cant differences appeared between treatment groups in
baseline vital signs or laboratory testing, except weight
(P = 0.05). These same characteristics in the historic
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relapse control cohort are shown at the far right of Table 1
for reference without statistical comparison to randomized
arms because no comparisons were made with this cohort.
The non-randomized control subjects were essentially
similar to the randomized treatment subjects in all demo-
graphic and clinical/laboratory respects.
Table 2 lists the frequency, distribution, and charac-
ter of illness among the three randomized arms at en-
rollment. Most subjects (127/180) were diagnosed with
P. vivax after complaining of illness, but a minority
was discovered during routine blood survey of the bat-
talion (53/180). Illness was mild in most cases and
dominated by headache, fever, chills, or muscle ache. A
few subjects did suffer moderate illness with nausea or
vomiting (12/180).
Assessments to 63 days
Physical complaints resolved within several days. Nausea,
vomiting, and headache occurred in fewer than 3 of 60
subjects among treatment arms. Adverse events of grade 3
or higher occurred among five, three, and one subject
receiving AS + PQ, AS-PYR + PQ, and DHA-PP + PQ,
respectively. None were definitely related to drug, and
two were probably related to drug (vomiting with AS-
PYR + PQ). Seven subjects were hospitalized during the
study and each was classified as having experienced a
serious adverse event unrelated to acute malaria or
study drugs (dengue and typhoid fever, ureteric stone,
nephrolithiasis, head trauma, fractured metacarpal, and
gastroenteritis).
Most blood chemistry and cell counts were normal at
enrollment and did not deviate during follow-up. How-
ever, lymphocytes, platelets, granulocytes, total bilirubin,
and hemoglobin were abnormal but returned to normal
(Fig. 3): depressed lymphocytes within three days; de-
pressed platelets at seven days; elevated granulocytes at
three days; and elevated total bilirubin at three days. De-
pressed hemoglobin did not recover within 14 days, but
did by day 63. All of these changes were attributed to
acute malaria and recovery from it.
Fig. 2 Study flow diagram
Table 1 Baseline demographic, laboratory, and clinical features
Baseline feature Randomized treatment assignment p-value Historic relapse control
AS + PQ AS-PYR + PQ DHA-PP + PQ AS alone
Subjects 60 60 60 – 41
Mean age (range) 29.4 (25–45) 28.6 (21–45) 29.5 (23–50) 0.54 27.7 (22–39)
Mean kg weight (range) 69 (55–87) 71 (54–88) 67 (52–88) 0.05 67 (52–90)
Tympanic °C
Mean 37.1 37.3 37.2 0.37 36.7
Mean g/dL
Hemoglobin 13.8 13.9 13.5 0.54 14.2
Mean %
Methemoglobin 1.39 1.42 1.46 0.35 1.48
Median parasites/μL blood (range) 744 (16–7664) 888 (32–6016) 880 (16–9488) 0.94 1408 (32–15248)
WBCs × 103/μL 7051 6886 6945 0.66 7700
Platelets × 103/μL 171 166 161 0.75 167
Glucose mg/dL 106 108 103 0.73 108
Bilirubin mg/dL 1.03 0.97 1.04 0.69 1.08
AS artesunate, PQ primaquine, PYR pyronaridine, DHA-PP dihydroartemisinin-piperaquine
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Liver and other blood chemistry values changed after
initiating therapy (Fig. 4). Aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) levels be-
came significantly elevated at days 3 and 7 in the group
receiving AS-PYR (P = 0.00001 and P = 0.0032), but not
with AS or DHA-PP for either AST or ALT (P = 0.30-0.86).
The AS-PYR median AST and ALT values, although ele-
vated above baseline, remained within normal limits, except
for a minority of subjects (Fig. 4). Those AST and ALT me-
dian values in the AS-PYR group each returned to baseline
values by day 14, and total bilirubin declined normally (by
day 7) in this group. No detectable changes to QTc interval
occurred during therapy with AS (day 1 vs. day 3, P = 0.92)
(Fig. 4). Modest QTc elongation occurred during treat-
ment with AS-PYR + PQ and DHA-PP + PQ: day 1 vs.
day 2, P = 0.0083 and P = 0.0285, respectively (Fig. 4).
The effect lingered to day 7 with AS-PYR + PQ (P =
0.0074) but not to day 14 (P = 0.252). The effect with
DHA-PP + PQ was absent by day 7 (P = 0.82). Among
all treatment groups, methemoglobin levels increased
from a baseline of about 1 % to 5–6 % within ten days,
and became normal within two weeks post-dosing of
PQ (Fig. 4).
Relapse control
Figure 5 illustrates weekly cumulative incidence of relapse
among randomized treatment arms during 52 weeks. The
graph also illustrates relapse among 41 soldiers enrolled in
another study and randomized to AS only (no PQ), the
historic relapse control in the current study. Thirty-six
soldiers in the current trial at Sragen were diagnosed
with vivax malaria but not enrolled in the current study
and received DHA-PP only (see Fig. 2). Many later re-
ported to the study clinic with confirmed relapse. These
Table 2 Illness at enrollment
Treatment assignment Total
AS + PQ AS-PYR + PQ DHA-PP + PQ
Subjects 60 60 60 180
Diagnosis with illness 42 43 42 127
Diagnosis without illness 18 17 18 53
Headache 30 35 24 89
Fever 19 27 24 70
Muscle ache 12 14 6 32
Chills 12 8 10 30
Malaise 5 3 6 14
Nausea 1 6 1 8
Vomiting 1 0 3 4
AS artesunate, PQ primaquine, PYR pyronaridine,
DHA-PP dihydroartemisinin-piperaquine
Fig. 3 Abnormal blood values at enrollment. Graphs illustrating blood laboratory values that significantly changed during the course of treatments
among groups. Each graph shows median (horizontal line), interquartile range (box), 1.5 times that range (horizontal line), and outlying observations
(points). The lightly shaded area shows the range of normal values
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observational findings allowed an independent assess-
ment of the per-protocol relapse historic control as a
surrogate of relapse attack in this trial: incidence
density 2.7/person-yr vs. 2.5/person-yr (P = 0.9); one-
year cumulative incidence of relapse 78 % vs. 75 % (P =
0.79), respectively.
Therapeutic efficacy
All subjects cleared asexual parasitemia by day 3. Most
subjects were gametocytemic at enrollment (121/160),
representing 60 %, 62 %, and 70 % rates among AS + PQ,
AS + PYR, and DHA-PP groups, respectively (P = 0.342).
Gametocytemia occurred more frequently among symp-
tomatic (98/127, 77 %) compared to asymptomatic (23/53,
43 %) subjects; OR = 4.4 (95 %CI = 2.2-8.8;P < 0.0001). The
initial geometric mean (range) per μL of 128(16–1232),
80(16–1200), and 64(16–1200) among those respective
groups (P = 0.287) vanished within 24 hr of initiating ther-
apy except in one, one, and two subjects. All were free of
microscopically patent gametocytemia by day 3. Table 3
summarizes primary endpoint analyses estimating efficacy
of PQ against relapse when combined with AS, AS-PYR,
or DHA-PP. The groups of 60 subjects experienced ten,
nine, and seven relapses, respectively, with only three sub-
jects being lost to follow-up. Relapses occurred between
day 39 and 270, with median day of relapse among groups
at 78, 128, and 104, respectively. Therapeutic efficacy by
incidence density was 92 %, 94 %, and 95 %, respectively,
with 95 % confidence intervals between 83 %-98 %. Sub-
jects >70 kg were not more likely to relapse (OR = 0.92;
95%CI = 0.4-2.3; P = 0.99). Estimates of efficacy by propor-
tion of subjects remaining free of recurrence at six
months, a secondary analysis for the sake of reference to
other studies possibly confounded by reinfection, were
83 %, 88 %, and 88 % for AS +QN, AS + PYR, and DHA-
PP, respectively.
Discussion
This randomized trial of 0.5 mg/kg PQ daily for 14 days
concurrent with AS-PYR or DHA-PP for radical cure of
vivax malaria demonstrated good safety, tolerability, and
efficacy for these options. All subjects cleared parasitemia
by day 3 and none recurred before day 39, affirming good
efficacy of AS-PYR and DHA-PP against the asexual
blood stage parasites [18–21]. Initially high rates of game-
tocytemia rapidly cleared (<72 hr). Relapse occurred
among 9/60 (15 %) and 7/60 (12 %) subjects assigned
AS-PYR or DHA-PP, respectively. Incidence density
was applied as the preferred mathematical treatment to de-
rive estimates of therapeutic efficacy involving prolonged
Fig. 4 Changes in liver and blood chemistry and QTc values prior to and up to 63 days following treatment commencement of therapy. Graphs
illustrating liver and blood laboratory values and QTc measurements that significantly altered after the commencement of therapy among groups. Each
graph shows median (horizontal line), interquartile range (box), 1.5 times that range (horizontal line), and outlying observations (points). The lightly shaded
area shows the range of normal values, except for ΔQTc which reflects the mean ΔQTc ± standard deviation. MetHb measurements for AS + PQ represent
days post-dosing with PQ (commencing on day 9 post-patency). MetHb methemoglobin, AS artesunate, PQ primaquine
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periods of follow-up [30–32]. We estimated the efficacy
of radical cure by AS-PYR + PQ and DHA-PP + PQ at
94 % and 95 %, respectively (Table 3), each with good
tolerability.
Drug-related changes occurred among subjects. The
significant elevation of AST/ALT in a minority of sub-
jects receiving AS-PYR (5/60) has been reported in other
studies [33]. QTc elongation appeared in subjects taking
AS-PYR and DHA-PP, but not AS + PQ (Fig. 4). These
effects are known with those compounds and were not
exacerbated by primaquine (daily 0.24 mg/kg dosing) in
DDI studies in healthy volunteers [16, 17]. The data in
the current trial are consistent with those observations.
Consumption of a carbohydrate snack immediately prior
Fig. 5 Relapse attack among groups during year after therapy. Relapse timing and extent among treatment groups (AS + PQ, solid black; AS-PYR + PQ,
black dashed; DHA-PP + PQ, black dotted) in the current trial. The upper solid red line (AS) represents the relapse control group used as the denominator
in estimating efficacy, taken from a prior trial in soldiers deployed to the same region [7]. The other upper red line that is dashed (ACT only) represents
relapse events among 39 soldiers with vivax malaria at Sragen who declined participation and were treated with DHA-PP but without
primaquine. AS artesunate, PQ primaquine, PYR pyronaridine, DHA-PP dihydroartemisinin-piperaquin
Table 3 Primary endpoint analysis and therapeutic efficacy
Treatment assignment Relapse control
AS + PQ AS-PYR + PQ DHA-PP + PQ
Subjects 60 60 60 41
Withdrawals 2 1 0 0
Relapses 10 9 7 32
Efficacy by incidence density
Person-years at risk 50.17 53.62 55.00 11.83
Relapse incidence density
(attacks/person-yr)
0.20 0.17 0.13 2.71
Efficacy (%) against relapse (95 % CI) 92.2 (83.4 – 96.6) 93.5 (85.7 – 97.3) 95.0 (88.3 – 98.2) na
Efficacy by proportion relapse-free at 6 months
Relapses within 6 months 10 7 7 na
% free of recurrence at 6 Months 83 88 88 na
AS artesunate, PQ primaquine, PYR pyronaridine, DHA-PP dihydroartemisinin-piperaquine
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to each primaquine dose very likely explains the rela-
tively very low rates of vomiting despite high dose
primaquine [27].
The AS + PQ treatment in the current trial tested the
hypothesis that PQ requires concurrent blood schizonto-
cidal therapy for good efficacy against hypnozoites. In
1955, Alving et al. [23] demonstrated inferior efficacy of
PQ administered after quinine therapy (15/19 relapsed)
relative to concurrent administration of same therapies
at the same doses (2/19 relapsed) among those ran-
domized groups. We administered AS first, then com-
menced PQ after a two day washout; 10/60 subjects
relapsed, but no more frequently than among the other
two treatment arms (P > 0.5). A higher total dose of PQ in
the current trial (7 mg/kg) compared to Alving et al. [23]
(3.5 mg/kg) likely explains the good efficacy of PQ despite
otherwise similar treatment (artesunate and quinine are
each efficacious against asexual blood stages and elimi-
nated within 24 hr of dosing). PQ at the higher dose may
thus be administered after treating the acute attack with
assurance of good efficacy. This offers a therapeutic option
when concurrent administration is either inconvenient or
contraindicated. Primaquine at the 7 mg/kg total dose
may thus commence at any point after therapy of acute
malaria, or presumptively without an acute attack (as with
post-travel presumptive anti-relapse therapy) with as-
surance of good efficacy.
PQ is prescribed at a total dose of either 3.5 or
7.0 mg/kg over 14 days, depending upon geographic ori-
gin of infection [34]. The New Guinea Chesson strain
responded to daily 7.0 mg/kg, but not 3.5 mg/kg [35].
Studies confirm the tolerance of P. vivax strains from
tropical Southeast Asia and New Guinea to the lower
dose [25, 35, 36]. Despite applying the higher dose under
direct supervision, 14 % (26/180) of our subjects re-
lapsed. Possible explanations include hypnozoite resist-
ance to PQ [37], and cytochrome P-450 2D6 (CYP2D6)
polymorphisms impeding conversion of PQ to active
metabolites [38, 39]. We are now examining CYP2D6
polymorphisms among the therapeutic failures in this
trial and anticipate reporting these findings in the near
future. Uncertainty regarding the basis of relapse despite
high dose PQ therapy is a limitation of this study.
In addition to the primary incidence density endpoint
analysis, Table 3 also shows crude estimates of efficacy as
expressed by proportion of subjects remaining free of re-
current parasitemia after six months. This endpoint has
been used in trials of hypnozoitocides and meta-analyses
of them. Those trials were conducted where reinfection
among treatment groups could not be excluded, or where
variable risks and timing of natural relapse was not con-
trolled in trial design. In other words, rather than report
efficacy against relapse, those trials simply compare the
effect of hypnozoitocidal therapy upon rates of recurrence
from any source of bloodstream infection. In the trial re-
ported here, by virtue of near certainty regarding the ab-
sence of confounding by recrudescence (wholly effective
blood schizontocides) or reinfection (absence of risk at the
study site), along with a relapse control arm (risk and rate
of relapse without primaquine therapy), we were able to
report therapeutic efficacy of primaquine against relapse
using incidence density risk analysis.
This trial provided robust estimates of PQ efficacy
against relapse when combined with modern therapies.
The findings of good safety, tolerability and efficacy in
this trial reassures, but does not address the serious
problem of PQ effectiveness. PQ often fails because it
is: 1) unavailable or prohibited [40]; 2) rarely pre-
scribed [41]; 3) withheld from patients who may be
pregnant, <1 yr of age, or deficient in G6PD [34]; 4)
not offered to patients of unknown G6PD status [42];
5) not completed by the patient [43]; or 6) disabled by
CYP2D6 polymorphisms [37, 38, 44]. The sum of these
potential pitfalls deeply erodes PQ effectiveness in routine
practice in the often-impoverished endemic areas of the
tropics. Good efficacy is the starting point for then ad-
dressing a range of barriers to the good effectiveness that
realizes maximum clinical and public health impacts.
Conclusions
Patients with P. vivax receiving AS-PYR + PQ or DHA-
PP + PQ enjoyed good tolerability, safety and efficacy of
these regimens. AS-PYR and DHA-PP may thus be con-
sidered validated options to chloroquine for radical cure
of P. vivax with PQ. Further, PQ at 7 mg/kg total dose
does not require concurrent administration of blood schi-
zontocide for good efficacy. PQ may thus follow therapy
with untried blood schizontocides for either therapy or
chemoprophylaxis with the expectation of good efficacy.
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